Literature DB >> 3656312

Adrenal suppression following low-dose topical clobetasol propionate.

E M Ohman1, S Rogers, F O Meenan, T J McKenna.   

Abstract

The use of topical steroids is associated with adverse systemic effects such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and application of more than 50 g per week of clobetasol propionate cream has been shown to cause secondary adrenal failure. We describe 4 patients who used clobetasol propionate cream over a prolonged period; 3 patients used less than 50 g per week (7.5, 25 and 30 g per week) and yet all developed secondary adrenal failure for up to 4 months after cessation of therapy. Adrenal insufficiency following prolonged use of clobetasol propionate in moderate dosages may therefore be more common than previously recognized. It is suggested that the metyrapone test, which conveniently examines the entire HPA axis, should be employed in patients receiving long-term topical clobetasol propionate cream and that glucocorticoid supplementation should be given during episodes of stress, such as infections and surgery, for up to 4 months after cessation of therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3656312      PMCID: PMC1290902          DOI: 10.1177/014107688708000709

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  14 in total

1.  Effect on adrenal function of topically applied clobetasol propionate (Dermovate).

Authors:  C F Allenby; R A Main; R A Marsden; C G Sparkes
Journal:  Br Med J       Date:  1975-12-13

2.  Pituitary-adrenal function after topical steroids.

Authors:  J N Cooke; K D Crow
Journal:  Lancet       Date:  1967-12-09       Impact factor: 79.321

3.  Pituitary-adrenal function after occlusive topical therapy with betamethasone-17-valerate.

Authors:  V H James; D D Munro; M Feiwel
Journal:  Lancet       Date:  1967-11-18       Impact factor: 79.321

4.  Pharmacokinetics. Pharmacokinetic factors affecting epidermal penetration and percutaneous adsorption.

Authors:  S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

5.  Percutaneous absorption of corticosteroids: systemic effects.

Authors:  R B Scoggins; B Kliman
Journal:  N Engl J Med       Date:  1965-10-14       Impact factor: 91.245

6.  [Pituitary adrenal axis activity during topical treatment with 0,075 g% triamcinolone benetonide cream (author's transl)].

Authors:  J Meynadier; B Guillot
Journal:  Dermatologica       Date:  1982-05

7.  Adrenocortical suppression with topical flumethasone.

Authors:  R D Carr; R G Wieland
Journal:  Arch Dermatol       Date:  1967-09

8.  The effect of percutaneously absorbed steroids on hypothalamic--pituitary--adrenal function after intensive use in in-patients.

Authors:  D D Munro
Journal:  Br J Dermatol       Date:  1976-03       Impact factor: 9.302

9.  Cushing's syndrome and pituitary-adrenal suppression due to clobetasol propionate.

Authors:  R C Staughton; P J August
Journal:  Br Med J       Date:  1975-05-24

10.  Adrenal function during topical oral corticosteroid treatment.

Authors:  T Lehner; C Lyne
Journal:  Br Med J       Date:  1969-10-18
View more
  14 in total

1.  Adrenal insufficiency secondary to inappropriate oral administration of topical exogenous steroids presenting with hypercalcaemia.

Authors:  Rahila Sarwar Bhatti; Michael D Flynn
Journal:  BMJ Case Rep       Date:  2012-06-21

2.  Importance of a thorough drug history in presurgical patients.

Authors:  Shibby Robati; Mohammad Kamren Shahid; Adrian Vella; Adrien Vella; Simon Rang
Journal:  BMJ Case Rep       Date:  2014-03-14

3.  Linear growth arrest without weight gain due to overuse of topical clobetasol.

Authors:  Zahra Razavi; Milad Sanginabadi
Journal:  Oman Med J       Date:  2014-11

4.  Using pH abnormalities in diseased skin to trigger and target topical therapy.

Authors:  Khalida Rizi; Rebecca J Green; Michael X Donaldson; Adrian C Williams
Journal:  Pharm Res       Date:  2011-05-26       Impact factor: 4.200

5.  Osteoporotic vertebral fracture caused by topical corticosteroid abuse: A case report.

Authors:  Stefano Piaserico; Dennis Linder; Francesco Messina; Mauro Alaibac
Journal:  Exp Ther Med       Date:  2019-07-30       Impact factor: 2.447

6.  Herbal creams used for atopic eczema in Birmingham, UK illegally contain potent corticosteroids.

Authors:  H M Ramsay; W Goddard; S Gill; C Moss
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

Review 7.  Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a Review of the Literature and Suggested Monitoring Tool.

Authors:  Ratika Gupta; Luz S Fonacier
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

8.  Iatrogenic Cushing's Syndrome with Subsequent Adrenal Insufficiency in a Patient with Psoriasis Vulgaris Using Topical Steroids.

Authors:  Suzan Demir Pektas; Gursoy Dogan; Nese Cinar
Journal:  Case Rep Endocrinol       Date:  2017-11-13

9.  Rational and ethical use of topical corticosteroids based on safety and efficacy.

Authors:  Sanjay K Rathi; Paschal D'Souza
Journal:  Indian J Dermatol       Date:  2012-07       Impact factor: 1.494

10.  Systemic side-effects of topical corticosteroids.

Authors:  Sandipan Dhar; Joly Seth; Deepak Parikh
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.